In maximal settings, for patients with left-sided colon cancer and known KRAS/NRAS wild type (WT) molecular status, anti-EGFR antibodies such as cetuximab or panitumumab may be added to chemotherapy doublet, with a moderate-strength recommendation. Here, EGFR is linked to malignant colon neoplasm.